Fundamental Data for MDCO

MEDICINES(NSDQ:MDCO)

Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment ofpatients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.

# Employees: 453

Address: 8 Campus Drive,Parsippany,NJ,USA

Phone: 973 656-1616

Fax: 973 656-9898

Website: www.themedicinescompany.com

Email: ir.themedicinescompany.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Clive A. Meanwell (Chmn.; C.E.O.)

John P. Kelley (Presi.; C.O.O.; Dir.)

Glenn P. Sblendorio (Exec.V.P.; C.F.O.; Treas.; Princ. Acttg. Off.)

William W. Crouse (Dir.)

Robert J. Hugin (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/17/2010

Mean EPS (Next Qtr): ($0.18)

Mean EPS (Year): ($0.22)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 7

Shares Performance

Period	MDCO	Compare to S&P
YTD	-49.22 %	-57.97 %
4 Weeks	-13.63 %	-14.56 %
12 Weeks	-1.19 %	-6.84 %

Shares Information

Analyst Coverage: Y

Avg Volume: 372347

Shares Outstanding: 52M

Market Cap: $0.39B

52 Week High: $16.58

52 Week Low: $6.47

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 MDCO split by factor of 0.250

Earnings Performance

EPS Growth in Last Quarter: -185.71 %

EPS Growth in Last Year: -0.01 %

Sales Growth in Last Quarter: -5.17 %

Sales Growth in Last Quarter: 12.10 %

Financials

Qtr Book Value: $1.27

Cash Flow/Share: $50.43

Change in Payout Ratio: -0.010

Price/Sales: 1.000